Mode
Text Size
Log in / Sign up
Phase 1 N=157 Randomized Quadruple-blind Diagnostic

Defining Vitamin D Insufficiency in School Age Children: A Randomized Placebo Controlled Trial of Vitamin D3

Healthy

Enrolled (actual)
157
Serious AEs
0.0%
Results posted
Oct 2015
Primary outcome: Primary: Serum 25-hydroxyvitamin D — 26.7; 22.4 ng/mL — p=0.003

Study Design & Population

Study type
Interventional
Phase
Phase 1
Interventions
Vitamin D3 1000 IU (Dietary_supplement); Placebo Tablet (Dietary_supplement)
Age
Pediatric · 8+ yrs
Sex
All
Sponsor
University of Pittsburgh
Primary completion
Oct 2011

Outcome Measures

OutcomeResultp-value
PRIMARY
Serum 25-hydroxyvitamin D
26.7; 22.4 0.003 sig
SECONDARY
Parathyroid Hormone (PTH) Dietary Data
35.5; 33.5 0.51
SECONDARY
Osteocalcin (OC)
101.1; 104.8 0.66
SECONDARY
Collagen Type 1 Cross-linked C-telopeptide (CTx)
1.4; 1.6 0.35

Summary

The study objective is to characterize the threshold levels of serum 25-hydroxyvitamin D for the definition of vitamin D insufficiency in 8-14 year old African American and Caucasian children. We propose a 6 month randomized placebo controlled trial of vitamin D (vitamin D3 1000 IU/day vs. placebo) initiated during October through March (during fall and winter) in 8 to 14 year old African American and Caucasian children. The results of the trial will help establish the cutoff threshold value of serum 25(OH)D for defining vitamin D insufficiency in preadolescent and adolescent children. Safety of vitamin D supplementation will be assessed by measuring serum calcium at 0, 2 and 6 months and by monitoring for adverse events. Currently recommended adequate intake for vitamin D of 200 IU daily may not meet the body's daily needs for vitamin D. Therefore, it is likely that a higher level of daily vitamin D intake may be needed to meet the body's skeletal and non-skeletal demands for vitamin D. Determining the dietary required intake of vitamin D for the prevention of vitamin D insufficiency during childhood has immense public health potential for addressing health disparities and ensuring better bone health during adulthood. The primary outcome measure will be serum 25(OH)D and parathyroid hormone (PTH). The secondary outcome measures will include: markers of bone formation (serum P1NP) and bone resorption (serum CTX).We will also examine differences in serum 25(OH)D, PTH, and markers of bone turnover in African American vs. Caucasian children.

Eligibility Criteria

Inclusion Criteria

  • Age: 8-14 years
  • Race: African American or Caucasian
  • Children not taking multivitamins for at least 1 month before enrollment and agree not to start any multivitamin supplements during the 6-month trial period.
  • Children who are on multivitamins can be considered for enrollment only if they are able to and agree to stop their multivitamin tablet for a 1 month washout period prior to enrollment.
  • Absence of chronic diseases that could affect growth or calcium or vitamin D metabolism

Exclusion Criteria

  • Hepatic or renal disease
  • Metabolic rickets
  • Malabsorptive disorders (Crohn's disease, cystic fibrosis and celiac disease) or cancer
  • Treatment with anticonvulsants or systemic glucocorticoids
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00732758). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search